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Introduction 
Gentamicin has its origins in Jamesville, N.Y. mud and Syra¬ 
cuse, N.Y. park loam. At least the micro-organisms which pro¬ 
duce gentamicin, Micromonospora echinospora and Micromonospora 
purpura. were Isolated from these mud and loam specimens. This 
new antibiotic complex was first reported in 1963 by Weinstein, 
Luedemann, Oden and Wagman (l). In a later article the same 
authors characterized this drug as a basic, stable, water 
soluble, and broad spectrum antibiotic complex which was ex¬ 
tracted by cationic exchange resin and differentiated from 
other similarly extracted antibiotics by comparative paper 
chroma togr a phy. 
In vitro efficacy? Weinstein, et al. (1) reported an in¬ 
creased unit potency of gentamicin over kanamyein or neomycin in 
mice infected with Klebsiella pneumonia. Staphlococcus auerus, 
Salmonella schottmuelleri. Diplococcus pneumoniae. Pseudomonas 
aeruqineoa. and Streptococcus pyogenes. At the same time, White 
(2) reported in vitro inhibition of between 20 and 60 strains each 
of Staphlococci, Proteus, Psuedomonas, E. coli and Aerobacter 
aeroqenes with a gentamicin concentration of 4 jug/ml. Ninety- 
five percent of all strains were inhibited by this concentration 
except for Proteus which required 15jag/ml to inhibit all species. 
Bactericidal levels were observed to be within two tube dilutions 
of bacteriostatic concentrations. Also during 1964, Klein, 
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Eickhoff, and Finland (3) reported in vitro inhibition of most 
Staphlococci, Salmonella, Herella, and Klebsiella-aerobacter 
with a concentration of 3.lug/ml whereas 6.2-25ug/ml were re¬ 
quired to inhibit E. coli. Meningococci, Streptococci, Diplococcus 
pneumoniae, Ps. Aeruginosa, and Prot<3Us. By 1970, Rubenis, Kazij 
and Jackson (4) had tested approximately 100 strains each of 
Klebsiella, Aerobacter, Psuedomonas, E. coli, and Proteus species 
and found the minimum inhibitory concentrations (MIC's) of genta¬ 
micin to be 0.8, 1.6, 3.1, and 12,5 jug/ml respectively. Weinstein, 
et al. (l) noted that strains of E. coli and S. Aureus resistant 
to streptomicin and streptothricin were sensitive to gentamicin 
but that those resistant to kanamycin and neomycin were also re¬ 
sistant to gentamicin. Klein, et al. (3) reported that organisms 
resistant to streptomycin, kanamycin or neomycin were sensitive to 
gentamicin whereas those made resistant to gentamicin were resistant 
to the other aminoglycosides as well. These authors felt this was 
evidence for possible "unidirectional cross resistance." As can 
be imagined, these initial reports of marked activity of this 
drug against gram-negative organisms as well as against many gram¬ 
positive bacteria quickly stimulated investigations into the methods 
of action and excretion, the dose/concentration relationship, and 
the possible toxicities of gentamicin. 
Mechanism of action: Rosselet and co-workers (5) initially 
characterized the antibiotic complex as an aminoglycoside. Rine¬ 
hart (6) later termed gentamicin an "aminoglycosidic aminocyclitoi." 
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This term refers to any compound in which a sugar containing 
an amino group is attached via a glycosidic linkage (amino¬ 
glycoside) to another fragment containing a cyclitol unit 
where one or more hydroxyls are replaced by amino groups (amino- 
cyclitol). Two subclasses exist, one containing streptidine- 
(streptomycins), and the other containing deoxystreptanine- 
(neomycins, kanamycins, paromycins and gentamicin). The exact 
mechanism of action of these antibiotics has yet to be eluci¬ 
dated, although arrest of protein biosynthesis within minutes 
following the addition of gentamicin was observed by Hahn 
and Sarre (7). These investigators commented, "The finding that 
nucleic acid biosynthesis is relatively unaffected by gentamicin 
renders observations on the failure of protein synthesis highly 
significant. We conclude that gentamicin is a specific inhibitor 
it 
of protein biosynthesis in susceptible bacteria (7). Because 
gentamicin shares many common features with streptomycin con¬ 
cerning effects on cell protein synthesis (8), Davies has ob¬ 
served (9) that its mechanisms of action may mimic that of 
streptomicin which binds to the 305 ribosomai subunit, inter¬ 
feres with the function of the A site and prevents irreversibly 
further protein synthesis (10). Lorian notes that gentamicin 
interferes with the translation mechanism producing a misreading 
by messenger RNA which results in a nonsense polypeptide (ll). 
_ __L 
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Resistance; Consistent with the above mechanism, is 
the finding that gentamicin resistant mutants have been iso¬ 
lated which produce altered ribosomal proteins (9). Resistant 
pseudomonas species utilizing this mechanism have been isolated 
in burn wound units (12). More commonly, resistance in clinical 
situations is due to the presence of extra chromosomal elements, 
R-factors, which enzimatically deactivate gentamicin by esteri¬ 
fication or hydroxyl groups or acetylation of amino groups (9). 
Serum levels: Black, Calesnick, Williams and Weinstein 
(13) found peak serum levels occurred one hour after injection 
of 0.2-3.2 mg/kg intramuscularly (IM) into healthy human subjects. 
Activity could still be demonstrated 6 hours later with the low 
doses and 12 hours later with high doses. The peak blood level 
in iaicrograms per milliliter was generally four to six times the 
administered dose in milligrams per kilogram. Both Black, et ai. 
(13) and Riff and Jackson (14) found that approximately 30% of 
gentamicin was bound by serum proteins. Riff and Jackson (14) 
used radioactivity labeled gentamicin (C^4) to demonstrate a 10% 
binding to erythrocytes such that each alteration of 4 hemato¬ 
crit points inversely changes the serum level by 2 jag/ml. How¬ 
ever, McCracken, Chrane & Thomas (15) found no correlation be¬ 
tween peak serum levels of gentamicin and hematocrit in 58 
infants under two weeks of age. They questioned whether this 
discrepancy might be due to a different affinity of fetal red 
blood cells for gentamicin. 
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No accumulation of the antibiotic was seen after repeated 
injections in normal subjects (13) or in patients with BUN 
<^25 mg/100 ml (3). However, Klein, et al. (3) studied one 
patient who had a BUN of 105mg% at the end of a 9 day course of 
gentamicin therapy, and observed a serum level of 17ug/ml in this 
patient ten days after the final dose which suggested that im¬ 
paired renal function resulted in prolonged serum concentrations. 
Excretion: Initial renal clearance studies were carried out 
in the dog with low doses of gentamicin (1.39 and 1.76 mg/kg) which 
had no appreciable effect on urine flow, electrolyte excretion, 
creatinine clearance or glomerular filtration rate. The rate of 
clearance was approximately equal to the GFR and studies in humans 
showed almost complete recovery of the unchanged antibiotic with¬ 
in 24 hours following doses of 1.6 and 3.2 mg/kg (13). No other 
significant method of elimination was found. Gyselynck, Forrey 
and Cutler (16) did extensive studies on the pharmacokinetics of 
gentamicin in patients with differing degrees of renal function 
and observed that the renal clearance of gentamicin was similar 
to that of inulin. However, when the glomerular filtration rate 
was less than 2Qmg/min, renal excretion of gentamicin in 72 hours 
was less than 50% of the administered dose. McCracken's studies 
on excretion in infants and neonates demonstrated that percentage 
excreted was independent of weight but correlated directly with 
age and rates of creatinine clearance (17,18), and recommended a 
higher dose during the first week of life (7.5 rather than 5.0 
mg/kg/day) (15). 
, 
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Clinical trialsi Four patients (a woman with burns com¬ 
plicated by Pseudomonas septicemia^ a man with a staghorn 
caliculus and septicemia due to Proteus mirabilis, a third 
patient with septicemia due to Proteus and a fourth person 
with polycystic kidney disease and infection due to Pseudo¬ 
monas) were treated with gentamicin in March 1962. The last 
patient was cured with gentamicin after other antibiotics had 
failed but was the first to develop vestubuiar toxicity. 
Jackson, when describing these patients in his introduction to 
the Symposium on Gentamicin, in 1969, observed, "Thus the scope 
of the problem was characterized in these first 4 patients5 
both by the need for gentamicin or other drugs to control in¬ 
fections, especially serious infections with gram-negative bac¬ 
teria, and by some of the difficulties involved in the use of 
aminoglycoside antibiotics" p. 341 (19). 
Gentamicin since its first clinical application in 1962 has 
been used for all types of gram-negative bacterial infections and 
for many infections caused by gram-positive organisms. It has 
often been the drug resorted to after other antibiotic failures, 
and has commonly been used in severe septicemias and urinary tract 
infections. 
Use in Meningitis: Naturally then, gentamicin was tried in 
cases of gram-negative bacillary meningitis. Afflicted patients 
were usually neurosurgical patients, or neonates, often with 
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hydrocephalus or meningomyelocele, but the route of administra¬ 
tion has varied considerably. Some patients have received only 
systemic (IM or IV) gentamicin, others have had gentamicin ad¬ 
ministered only intrathecally (IT)? intraventricularly (iVt), or 
intracisternally (IC). Most patients with meningitis have received 
various combinations of systemic therapy and direct placement into 
cerebrospinal fluid (CSF). Rodrigues, et al. (20), found that 
systemically administered gentamicin does net readily enter 
the CSF when given to patients without inflamed meninges. In 
three of four patients receiving 3-4 mg/kg/day of gentamicin 
only intravenously, no CSF gentamicin activity was found despite 
peak serum concentrations of 2.6 to 5.2 jug/ml. In a CSF sample 
from the fourth patient drawn 3 hours after the IV infusion began, 
there was a concentration of 1.1 pg/ml. This level was approxi¬ 
mately 2($ of the patients* peak serum concentration observed 
one hour before the CSF sample was drawn. Riff and Jackson (14) 
found that in patients receiving systemic gentamicin without 
meningeal inflammation, CSF gentamicin levels were detectable 
only when serum levels were 4 Mg/nil or higher. 
Systemic use in infant meningitis: In contrast to the above 
data, several patients with meningitis have been successfully 
treated with only intramuscular gentamicin therapy. Klein, 
Eickhoff and Finland (3) described a prematurely born infant 
with a meningomyelocele who had been unsuccessfully treated for 
Pseudomonas aeruginosa meningitis with chloramphenicol and 
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polymyxin. At 5 weeks of age the infant began receiving 2mg/kg/day 
of gentamicin IM. Simultaneous serum and CSF samples, collected 
two hours after the last IM dose, had gentamicin levels of 0.73 
and 0.53 jug/ml respectively and resulted in prompt sterilization 
of the ventricular fluid. In 1969, Nunnery and Riley (21) reported 
9 cases of gram-negative bacillary meningitis in infants aged 1 day 
to 13 months treated with 1.2 mg/kg/day of IM gentamicin. Four in¬ 
fections were caused by Klebsiella-Enterobacter, 3 by Pseudomonas 
aeruginosa and 2 by E. coli. All the infections had not responded 
to multiple other antibiotics before gentamicin was begun. Seven 
infections responded favorably. One treatment failure occurred 
with Pseudomonas aeruginosa and the other with a Klebsiella in¬ 
fection. Two years later three infants with Proteus mirabilis and 
one infant with E. coli meningitis were described by Klein, et al. (22). 
These patients were given 3 mg/kg of gentamicin twice a day intramus¬ 
cularly. One patient with a proteus infection died 18 hours after 
therapy was started, the second patient with proteus meningitis, had 
only 1 day of therapy due to parental withdrawal of consent. A third 
patient infected with E. coli, received 1 mg IT after failure to 
sterilize the CSF with only systemic gentamicin therapy. However, 
this particular ogranism later required chloramphenicol for eradica¬ 
tion and was found to have a gentamicin MIC of 12.5 jug/ml. McCrakcen, 
Chrane and Thomas (15) treated seven neonatal meningitides with only 
systemic gentamicin, 6 with E. coli and 1 with Enterobacter infections. 
They reported obtaining sterile CSF in 3 within 36 hours. CSF in two others 
, ‘ 
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had become sterile before switching to gentamicin but they clinic¬ 
ally improved immediately with systemic therapy. Two additional 
infants required 5 and 7 days of treatment for CSF sterilization. 
These investigators stated that "the levels of gentamicin in 
cerebrospinal fluid following systemic administration were 
generally low (0.2-2.9 pg/ml) and directly related to the dosage 
and degree of meningal inflammation" p. S222 (15). They also 
found that the bactericidal titers of spinal fluid against the 
infecting organisms were consistenly 1:2 or less. In 1973, 
Zoumboulakis, et al. (23) presented data on 19 infants with gram¬ 
negative bacillary meningitis who had been treated with 3 mg/kg/day 
of systemic gentamicin after "initial" therapy with other antimicrob¬ 
ial agents had not resulted in improvement. Sixteen of these 
patients (10 E. coli, 2 Klebsiella, and 2 Proteus, 1 Pseudomonas 
and 1 mixed Pseudomonas and E. coli) had their infection "controlled" 
within 2-5 days of treatment with one systemic gentamicin. An infant 
with Klebsiella infection and one with Pseudomonas and E. coli menin¬ 
gitis died, and hydrocephalus developed in the infant infected 
with Pseudomonas. Serum and CSF gentamicin assays were not per¬ 
formed. The authors note that none of their patients received 
intrathecal or intraventricular gentamicin. They stated, "Never¬ 
theless our results are comparable with those of the few studies 
in the literature in which gentamicin was used intrathecally 
and/or intraventricularly for the treatment of infantile 
meningitis" p. 57 (23). 
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Efficacy of gentamicin instillation into CSF: In order to 
evaluate the statement of Zoumboulakis, et al., it is necessary 
to examine the reports of direct instillation of gentamicin 
into the CSF. Leedom, et al. (24) studied four infants 
aged 14 days to 4 months who received intrathecal (IT) or intra¬ 
ventricular (iVt) gentamicin in doses from 0.01 to 1.0 mg/day. 
The infection was cured in one patient. Another patient had 
sterile CSF when gentamicin was started, but did resolve an ab¬ 
normal glucose value on therapy. The third patient suffered 
a relapse, and the fourth infant failed to have sterile CSF 
after 9 days of IT therapy. These investigators pointed out 
that these four infants had received prior antibiotic regimens 
which had failed to cure their infections, and that they were 
older than the majority of neonates with meningitis. The authors 
also reviewed their experience with neonatal meningitis over 
the previous six years. Thirty-two of 54 infants with gram-nega¬ 
tive bacillary infections died (59^). Seven survived with severe 
neurological Impairment and 15 patients had no residual dysfunc¬ 
tion (24). Newman and Holt (25) reported their experience with 
12 cases of neonatal meningitis treated with gentamicin 1 mg/day 
intraventricularly and 2 mg/kg/day BA. In the first case, the 
authors titrated the CSF gentamicin concentration against the 
MIC (2 ug/ml) and MBC (5 ug/ml) of the infecting strain of 
Pseudomonas pyocyanea. An initial daily dose of 0.1 mg IVt 
and 1 mg/kg IM, was gradually increased to 1 mg IVt and 2 mg/kg 
BA on day 6 before adequate CSF levels of 3 jug/ml were attained. 
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However, CSF cultures were sterile three days after the initial 
dose. Two additional cases were similarly treated and required 
the same dosages. Nine additional cases were therefore treated 
with a standard dosage of 1 mg/day IVt and 2 mg/kg/day B4. 
Treatment was successful in nine of the 12 cases, 6 with Klebseilla, 
2 E. coli (l failure), 2 Ps. aeruginosa (both failures),l Ps. 
pyocyanea and 1 Proteus. These results caused the investigators 
to state "In our view, intraventricular treatment is essential, 
as effective CSF levels cannot be guaranteed with intramuscular 
administration alone." p. 475 (25). Two years later the same 
authors reported results (26) of 13 additional patients who had 
been "unselected" and in whom treatment of any type was"unlikely 
to succeed" in contrast to their earlier study (25) where * 
they now stated, patients were only treated with gentamicin if 
the MIC of the organism was low and other drugs were likely to be 
ineffective. The second group of thirteen patients resulted 
from their new hospital policy of treating all cases of clinical 
meningitis with IVt and IM gentamicin as soon as gram-pegative 
organisms were found in the CSF. Six of these latter 13 patients 
died of overwhelming infection within 24 hours, receiving only 
one IVt dose. Three patients (l Proteus, 2 coliform) were cured . 
Four patients were considered gentamicin failures, 2 of whom 
died (l Proteus and 1 coliform) and 2 of whom were cured with 
other antibiotics (l coliform and 1 Proteus). CSF gentamicin 
levels 24 hours after the intrathecal dose (24 hour CSF levels) 
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ranged between 6 and l.Q;ug ml. They found lower levels on the 
first day. Unfortunately, the terms "intrathecal'1 and "intra¬ 
ventricular" were used interchangably in their report (26) and do 
not allow certainty concerning the route of administration for 
comparison with later disputes concerning the effective distribu¬ 
tion of gentamicin within the subarachoid space. Laber, Kalthan 
and Mahgrefte (27) reported their results in treating meningitis 
in 14 infants born with spina bifida who received 0.5 to 8 mg/kg/day 
of IM gentamicin and 0*5 (2 cases) to 8 mg (10 cases) per day intra- 
ventricularly. These children had been started on a regimen of 
chloramphenicol IM and IVt and were changed to gentamicin a) if 
the organism was not sensitive to chloramphenicol, b) if a less 
toxic drug could be used, or c) because of failure to sterilize 
the CSF. Seven of the 14 died (3 infected with E. coli, 2 with 
Ps. pyocyanea. 1 with Proteus and 1 with Actinobacter anitratus). 
One infant with E. coli meningitis died later of other causes as 
did another infant infected with Mycoplasma pneumoniae, whereas 
another with E. coli lived but was retarded. Only four infants 
(2 Proteus, 1 E. coli. 1 Strep faecalis) survived without 
sequelae attributable to the ventriculitis. The MIC range of 
all organisms was 0*8-1.5 pg/ml, and 24 hour CSF levels varied 
from 0.5 to 130 jag/ml. Five of six infants with mean CSF levels 
below 6 „ug.ml died, whereas six of eight with average levels 
above 6 jug/ml recovered from their infection. Despite CSF 
levels greater than 2 jug/ml and in excess of the MIC in 11 of 
. 
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the 14 cases, increasing concentrations of gentamicin in the 
spinal fluid were directly associated with increasing cure rate. 
These authors observed that 24 hour CSF levels tended to rise as 
long as intraventricular therapy was given. Lorber, et al. (27) 
concluded that despite suboptimal doses in early patients, and 
delay caused by using another antibiotic initially, they had "fair 
success" in treating ventriculitis due to gram-negative organisms, 
and stated that gentamicin may be the initial drug of choice in 
such infections. Mathies, et al., (28) published results on 15 
episodes of gram-negative bacillary meningitis, in 13 patients 
11 of whom received intracisternal gentamicin. Six of these patients 
died but the CSF had been sterilized in 4 cases with 3 mg/kg/day IM 
and lmg/day intracisternally. Three patients survived with severe 
sequelae and two recovered completely. One infant's E. coli infec¬ 
tion was eradicated with systemic therapy and another with E. coli 
died after the first IM dose. Neither serum nor CSF assays were 
done in these cases. However, van der Waarde and van der Weil- 
Korstanje (29) reported CSF levels in a similar case, an infant 
born with spina bifida and afflicted with E. coli meningitis which 
was unresponsive to systemic kanamycin. Gentamicin at doses of 
8 mg/kg/day IM and 8 mg/day IVt produced serum levels of 1.8 
-5.0 yg/ml and CSF concentrations of 28-100 jug/ml and sterilized 
the CSF within 48 hours. 
Any summary of the reports of gentamicin efficacy in curing 
infantile meningitis caused by gram-negative organisms is compli¬ 
cated not only by the diversity of patients and their vaguely 
. v.: > !; 
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defined "host defenses," but also by the different infecting 
bacteria, and finally, by the method of administering the anti¬ 
biotic in its range of dosages. In fact, the most salient 
features of these studies is the unpredictable nature of CSF con¬ 
centrations of gentamicin in any one patient on a particular 
regimen. This feature leads to the firm conclusion that individual 
CSF and serum levels must be monitored for effective treatment of 
such a potentially lethal infection. Several less firm conclus¬ 
ions are thats l) Gentamicin does enter the CSF from the sys¬ 
temic circulation better when the meninges are inflamed; 2) that 
systemic therapy may cure infantile meningitis but that IT or IVt 
therapy results in higher CSF levels more reliably; and 3) that 
higher levels, often regardless of the MIC, are associated with 
higher cure rates. Finally it should be noted that gentamicin's 
poorest record occurred in the treatment of Pseudomonas meningitis 
where over half of the reported cases (6 of 11) were treatment 
failures. 
Gentamicin in Adult Meningitis: Although most series in the 
literature have been of neonatal or infantile meningitis, several 
case reports describe the use of gentamicin in adult CSF infection 
following trauma and/or neurosurgical procedures. Rubenfire, 
et al. (30) published a detailed account of the course of a 59 
year old patient with recurrent olfactory groove meningioma and 
subdural empyema with CSF infection by Paracolobactrum aeroqenoides 
sensitive only to Polymyxin B and gentamicin. Six days of ineffectual 
.. j. 
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Polymyxin B therapy was followed by IM, IT and "intra-abcess" (IA) 
gentamicin therapy over a 40 day course during which gentamicin 
levels in CSF, serum and abcess contents were monitored. Al¬ 
though these authors state that during meningeal inflammation 
CSF levels are 1/2 to 2/3 those of serum, data were not provided 
to support this conclusion since at no time was the patient receiv¬ 
ing IM gentamicin without also IA or IT instillations. An IM in¬ 
jection of 40 mg was given 8 days after cessation of all antibiotic 
therapy when meningeal inflammation had subsided. At that time 
simultaneous serum and CSF levels revealed an approximate ratio 
of 1:4. McHenry, et al. (31) also used gentamicin after failure 
of other antibiotics in an 18 year old male with E. coli meningitis 
following trauma. Despite a systemic dose of 3 mg/kg/day, improve¬ 
ment was not seen until a subcutaneous CSF reservoir of the Ommaya 
type allowed direct instillation of gentamicin into the ventricles. 
Scheidemandel, et al. (32) reported a case of persistant E. coli 
meningitis which responded promptly to 10 mg/d of IT and 5 md/kg/d 
of IV gentamicin. The CSF grew E. coli once after this therapy was 
initiated but, after the epidural foreign body (a bullet) was re¬ 
moved,, the CSF remained sterile with only IM gentamicin. Graybill, 
et al. (33) treated Enterobacter meningitis, which occurred in a 
60 year old man following removal of a posterior fossa meningioma, 
with 5 mg of intraventricular gentamicin which caused a grand-mal 
seizure and respiratory arrest. Return to Polymyxin B therapy 
permitted return of positive CSF cultures which had been negative 
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for the 24 hours after the one gentamicin dose. Cautiously these 
investigators again used IVt gentamicin, only 1 mg/d, and the in¬ 
fection was cured without further side effects. 
Occasionally, very high doses of gentamicin have been given 
to adult patients. Fasano, et al. (34) reported treating patients 
with 160 mg/d intrathecally without ill effect, and Smilack and 
McClosky (35) presented a case where a patient inadvertently 
received two doses of 160 mg of gentamicin intrathecally one day 
apart with no untoward effects except perhaps a mild radiculopathy. 
This patient had rapid sterilization of his CSF. As these 
case reports describe only cures, often unexpected, and provide 
no way of quantifying or characterizing treatment failures. These 
few reports, then, do little more than recommend a trial of genta¬ 
micin in adult meningitis caused by sensitive organisms. 
Such a trial was carried out recently by Rahal, et al. (36) 
on 21 adult patients. Only twelve of these patients had culture 
proven meningitis, four with Pseudomonas aeruginosa, three with 
Klebsiella, two with Serratia marcescens, one with Hemophilus 
parainfluenzae and two with Diplococcus pneumoniae (who were treated 
with penicillin G after return of the culture results). All patients 
received other antibiotics in addition to IM and IT gentamicin. Al¬ 
though the authors do not give a failure or cure rate for the genta¬ 
micin regimen, they do mention 3 patients who died despite IT 
therapy. Several patients received daily doses of 8, 12, and 20 mg 
■ .. 
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IT, but most were treated IT with 4 tog/d. CSF concentrations 
were determined in 18 patients at various times after the 4 mg 
IT dose and were found to decrease rapidly over 24 hours such 
that concentrations at 10-15 hours varied from less than 1 ug/ml to 
20 pg/ml while at 20 hours "two-thirds of the CSF levels were be¬ 
low 3 yg/ml." Unfortunately, the authors do not give the actual 
number of samples tested at this time but they did conclude that 
the IT dose ^iould be given every 18 hours to maintain adequate CSF 
concentrations. It is not possible to determine the efficacy of 
gentamicin in adult meningitis from Rahal's results since these 
workers do not give data for the bacteriologically proven infec¬ 
tions, even though they state that, "memingitis was clinically or 
bacteriologically eradicated from 16 of the remaining 19 patients; 
however 12 of these patients died of other causes during hospitaliza¬ 
tion." p. 1397 (36). Yet this report specifically details 4 deaths 
which occurred without CSF sterilization, and further states that 
"Eleven patients died within two months of treatment, primarily 
from the underlying disease." p. 1396 (36). Even though these 
numbers are confusing, gentamicin was shown in several instances 
to eradicate gram-negative bacillary meningitis, and some data 
concerning lumbar CSF concentrations plotted over time was obtained. 
Distribution of Gentamicin in the CSF: In 1972, Moellering 
and Fisher (37) reported a 16 month old infant with Proteus 
morqanii meningitis—treated first with IM gentamicin (6 mg/kg/d) 
which gave CSF levels of 0.5 and 0.3 .ug/ml, and then with 
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intrathecal doses of 1 mg/d, which gave peak lumbar CSF levels 
of 6.9 >>g/ml. However, three hours after an IT dose of 2 mg, 
lumbar CSF had a concentration of 10.3 jug/ml whereas a simul¬ 
taneous ventricular CSF level was only 1.2 ug/ml. Culture of 
the two samples revealed sterile lumbar fluid but ventricular 
fluid was still infected with Proteus. Over the following five 
days, daily intraventricular doses of 2 mg gave adequate levels, 
21-39 hours after injection, in both ventricular (2.4-10.0 jug/ml) 
and lumbar (3.1-5.0 pg/ml),CSF samples, and CSF cultures became 
negative within 24 hours. This is the only case report in the 
literature which provides simultaneous lumbar and ventricular 
CSF levels of gentamicin. It serves to highlight the controversy 
surrounding routes of antibiotic administration. It is clear from 
the above reports that injections of two or more milligrams of 
gentamicin into the CSF will reliably produce concentrations 24 
hours later of greater than 2.5 ug/ml in fluid drawn from the same 
site. Documented cases of therapeutic failure with IT gentamicin 
followed by success with IVt administration demonstrate the un¬ 
reliability of lumbar CSF concentrations as an index of adequate 
treatment. Animal studies have attempted to elucidate the factors 
governing distribution of a drug and/or contrast medium in the 
spinal fluid. Funkquist (38) found that in order to insure the 
passage of contrast medium in dogs from the lumbar region into 
the cervical area, fluid from the cervical subarchnoid space had 
I • . 
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to be removed before injection of the contrast. Also, the neck 
of the animal had to be in extension during the injection. 
Rieselbach, et al. (39) instilled 50 microcures of 1^1 rose bengal 
into the spinal fluid of monkeys, varying the volume of injection 
so as to comprise 0.7% to 42% of the estimated CSF volume. X-rays 
of slices of frozen spinal cord and brain revealed the extent of 
distribution one hour after injection and demonstrated the need to 
use an injection volume which is 25% of the total CSF in order to 
have distribution throughout the subarachnoid space. These in¬ 
vestigators also studied eight patients in whom radioactive gold 
was instilled in volumes greater than 10% of the CSF. Two hours 
later, all patients had basal cistern activity but the patient with 
the best overall distribution had also received the largest volume, 
33% of the estimated CSF. In another patient, rescanning 24 hours 
later showed distribution over the cerebral convexity consistent 
with the normal upward flow of CSF from the basal cisterns. The 
authors note that despite this and other instances of later dis¬ 
tribution, effective antibiotic therapy in cases of diffuse 
meningeal involvement requires immediate optimal distribution 
because of the relatively rapid decrease in concentration of most 
drugs (in contrast to gold) after intrathecal administration. 
Alazraki, et al., (40) studied monkey cisterns magna fluid after 
the animals had been given a hyperbaric solution containing 
amphotericin B, D^qW, and a radioisotope (specific gravity 1.034 
compared to 1.006 for CSF). Injection was followed by Trendelenburg 
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positioning. When compared to a normobaric solution given in 
the horizontal position, the cisternal concentrations of the 
first group were 4 times greater at 8 minutes and higher through¬ 
out the first 30 minutes, resulting in double the amount of anti¬ 
biotic in the cisternal fluid within the first half-hour. 
In summary, there is experimental evidence for a better in¬ 
tracranial distribution of an intrathecally administered drug when 
the injected solution is l) hyperbaric, 2) equal to or greater 
than one fourth the estimated CSF volume, and 3) followed by 
Trendelenburg position. These in vivo studies were carried out in 
patients or animals without meningitis and depend greatly on flow 
characteristics of the CSF which could be altered by an inflammatory 
meningeal process. In adults more direct clinical experience is 
needed to evaluate not only the optimal dose of gentamicin but the 
optimal site and procedure for injection. In infants easy access 
to the ventricular fluid via the anterior fontenelle makes the 
intrathecal versus intraventricular administration preferable. 
Toxicity: Since the first patients received gentamicin in 
1962, physicians have been looking for and finding incidents of 
gentamicin toxicity. These have been of four types: l) acute, 
immediate toxicities; 2) renal toxicity; 3) vestibular toxicity; 
and 4) auditory toxicity. To intelligently evaluate the usefulness 
of this antibiotic, the risk of each known toxic reaction must be 
measured against the known efficacy of this drug. In addition, the 
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physician must balance the toxicities of gentamicin against the 
significant mortality and morbidity rates which accompany gram¬ 
negative meningitis in adults and neonates. 
Acute toxicity: Initial studies were carried out in mice by 
Black, et al. (13), establishing an I-A-q of 430 mg/kg intraperito- 
nealiy and 75 mg/kg intravenously which indicated greater "acute 
toxicity" (undefined by the authors) than kanamycin and less than 
neomycin. However, the amount needed to achieve serum inhibitory 
antibiotic levels is 1/10 to l/20th that of either neomycin or 
kanamycin. During human clinical trials there have been only 
scattered reports of immediate toxic reactions. Klein, et al. 
(3) reported the occurrence of a maculopapular rash in a 43 year 
old woman being treated for klebsiella bacteremia which cleared 
within 48 hours after discontinuance of gentamicin. This patient 
had also been receiving an amphetamine drug and oral iron pre¬ 
paration for more than 3 weeks before the eruption. Later clinical 
trials have not supported this early single finding, so that the 
occurrence of a rash in a patient receiving gentamicin should init¬ 
iate investigation into other possible etiologies. Correspondingly, 
there have been reports of transient elevations in SOOT (3,22) 
which have not proven to be clinically significant. 
Any intrathecal injection is associated with its own morbidity. 
Seizures, pain, as well as sensory and motor function loss have 
followed intrathecal injections, especially in the case of cancer 

22 
chemotherapeutic agents such as methotrexate (41-43). When a 
seizure has followed the use of gentamicin for gram-negative 
bacillary meningitis, it is often difficult to determine the role 
of gentamicin in initiating the seizure. Although Newman and 
Holt (26) obtained neuropathological examination in two infants 
who died within one hour of the injection, one of whom had con¬ 
vulsions 10 minutes after injection, there was no evidence of 
damage other than gross hemorrhage. However, as described above, 
Graybill, et al. (33) did witness seizures and respiratory arrest 
in an adult immediately following intraventricular infusion. Many 
other adults and infants have received both IT and IVt gentamicin 
without acute adverse effects even when mistakenly high doses were 
given. After 10 years of clinical experience it is apparent that 
gentamicin is an antibiotic with few acute side effects, even when 
delivered into the cerebrospinal fluid. 
Nephrotoxicity: Several of the first reports on the pharma¬ 
cology of gentamicin discussed its nephrotoxicity, specifically 
acute tubular necrosis. Black, et al. (13) found that 50/o of 
rats died after two weeks of 160 mg/kg/d of gentamicin because of 
frank tubular necrosis. There was less renal pathology with lower 
doses and at 20 mg/kg/d no clinical, gross or histopathological 
changes were noted. However, all beagles receiving 40 mg/kg/d 
and one dog receiving 8 mg/kg/d died as a result of renal tubular 
necrosis. Klein, et al. (3) noted a rise in BUN in two of twenty- 
six patients receiving systemic gentamicin with no other apparent 
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cause for decreased renal function. In 1968 Falco, Smith and 
Arcieri (44) summarized the clinical experience in animals on 
the nephrotoxicity of gentamicin as compared to that of other 
aminoglycosides. They found nephrotoxicity to be greater than that 
of streptomycin, similar to kanamycin, and less than neomycin or 
polymyxin. These authors also evaluated 131 patients who had 
serial BUN values obtained before, during, or after treatment. 
Only 4 of 68 increases were classed as "probably"related to genta¬ 
micin and 16 as "possibly" related. The definitions of these cate¬ 
gories are not precise. The authors did state that the "possibly 
related" category included cases where there was neither positive 
evidence for gentamicin toxicity nor evidence for any other cause. 
Of these 20 cases, seven were reversible, 9 occurred in terminally 
ill patients and 4 had no followup. There was no demonstrable 
relationship between dose or duration of therapy and nephrotoxicity. 
The authors estimated the incidence of nephrotoxicity to be 2% or 
less and ranked it with that of streptomycin. Commenting on this 
study. Riff (45) also described her experience with 110 patients, 
15 of whom were noted to have a BUN rise of 5 mg or greater. The 
cause of the rise was often difficult to determine. She concluded 
that the clinical expression of nephrotoxicity is not very important 
in the use of gentamicin, and added that no late renal damage had 
been recognized. In 1971 Wilfert, et al., (46) supported the above 
view with the results of another review of 77 courses of therapy. 
At this time gentamicin was generally being used in doses twice as 
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large as during the earlier studies, 3-5 nig/kg/d vs. 1.2-3 
mg/kg/d. Five of the 32 instances in which the BUN or creatin¬ 
ine rose were thought due to gentamicin. All of these patients 
received more than five days of therapy and three patients had 
slight BUN elevations before therapy, suggesting some prior com¬ 
promise of renal function. In all of these patients the BUN 
gradually returned to pretreatment levels. 
It would appear that the use of gentamicin in patients with 
normal renal function rarely produces serious renal damage. How¬ 
ever, in patients with elevated BUN or serum creatinine values, 
who cannot excrete gentamicin at a normal rate, the antibiotic 
serum level rapidly rises. This rise increases the risk of toxicity 
at a time when the compromised kidney is unable to compensate for 
even slight tubular damage. To avoid precipitous renal failure, 
the BUN and creatinine levels should be noted before and during a 
course of gentamicin and should be closely monitored in patients 
with any sign of renal dysfunction. 
Ototoxicity? Significant eighth nerve toxicity of gentamicin 
was manifested in one of the first four patients to receive the 
new antibiotic. This woman suffered bilateral loss of vestibular 
function after a course of gentamicin (19). From the beginning, 
therefore, clinical investigators were sensitive to the ototoxic 
possibilities, both auditory and vestibular, of this drug. 
Animal studies were initiated to evaluate these effects. 
Black, et al., (13) examined cats for vestibular dysfunction as 
demonstrated by ataxia and impaired "righting reflex." He found no 
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evidence for ataxia with doses under 50 mg/kg/day, but did 
demonstrate ataxia on the fifteenth day with a dose of 
50 mg/kg/d. These results, seen also in beagle hounds, were 
similar to the effects of streptomycin and kanornycin at the same 
doses. However, since the therapeutic doses of gentamicin are 
1/10 to l/20th those of kanamycin and streptomycin, clinical 
vestibular toxicity was expected to be correspondingly smaller. 
In 1969, Hawkins, et al. (47) also demonstrated ataxia in cats 
with 10-80 mg/kg/day of gentamicin after periods ranging from 13 
days with the largest dose, to 113 days with the smallest. On post¬ 
mortem examinations of the vestibular apparatus, scarring and loss 
of hair cells was seen in the macula sacculi. When compared with 
streptomycin on a weight-for-weight basis, gentamicin was found 
by these investigators to be twice as toxic for the vestibular 
system and slightly more toxic to the cochlea. They also invoked 
the lower dose requirement of gentamicin as hope for a low clinical 
incidence of ototoxicity. Wersall, Lundquist and Bjorkroth (48) 
examined, by electron microscopy, the effects of locally applied 
solutions of gentamicin in the middle ears of guinea pigs. With 
dilute solutions, O.'S/o of gentamicin in saline, they saw degenera¬ 
tion of vestibular and cochlea sensory cells similar to that found 
after prolonged IV injections. These same findings were later con¬ 
firmed in cats (49). McGee, Webster and Williams (50) evaluated 
cat vestibular function by using electronystagomography. After 
fourteen days of 20 mg/kg/day of gentamicin, depression of post-rota¬ 
tory nystagmus and of the normal response to caloric irrigation was 
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observed in 60% of animals. Auditory function damage (measured 
via alterations in conditioned response patterns) occurred in 
only 6.6%. Sixty percent of these animals also demonstrated 
renal toxicity. The incidence of ototoxicity was higher and 
occurred earlier in this group than in the group without nephro¬ 
toxicity. Waitz, et al. (51) demonstrated in cats that renal and 
vestibular toxicity could be separated temporally with low doses, 
20 rag/kg/d where the vestibular dysfunction occurred before the 
renal. They also found that ataxic cats with evidence of renal 
impairment reversed this dysfunction within twenty days of stopping 
the antibiotic but remained ataxic for forty-five days. At this 
time gentamicin was resumed and death from renal tubular necrosis 
followed in 16-19 days. Igarashi and coworkers (52) did similar 
experiments with squirrel monkeys using proficiency at moving 
along a rotating rail as their measure of ataxia. Decreased pro¬ 
ficiency correlated with damage, seen histologically, to vestibular 
hair cells and in some cases degeneration of afferent nerve endings 
around the hair cells. They, too, demonstrated renal damage in 
almost every animal. It consisted of slight to severe tubular de¬ 
generation with glomerular changes in some animals. As with all 
other animal studies, high daily doses produced early severe 
renal damage. 
The first 27 patients who developed ototoxicity were re¬ 
ported at the First International Symposium on Gentamicin in Paris, 
1967 (53). Clinical characteristics common to this group included 
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age over 60 years, previous use of other ototoxic drugs, renal 
insufficiency, and plasma concentrations of gentamicin over 12 
JUg/ml. In 1971, Jackson and Arcieri (54) reviewed the total exper¬ 
ience in the United States in which gentamicin was reported to have 
possibly caused ototoxicity. They compared the clinical characteris¬ 
tics of these patients and details of 70 courses of gentamicin 
therapy to 843 gentamicin regimens without ototoxicity. In 20 
patients there was prior otologic disease, nonvestibular dizziness, 
transient symptoms, or symptoms with normal vestubular function 
tests. Two patients were critically ill or poorly responsive and 
four were also receiving kanamycin or streptomycin. These patients 
combined gave a total of 26 cases classed as doubtful or insignifi¬ 
cant gentamicin toxicity. The 44 remaining cases of ototoxicity 
were thought to be "probably caused by gentamicin." Two-thirds 
of this group had only vestibular symptoms, one-sixth had only 
auditory dysfunction and one-sixth had both types of ototoxicity. 
It should be noted that 14 of the 37 patients who developed signs 
and symptoms of vestibular dysfunction had only transient impair¬ 
ment. Animal studies have produced conflicting opinions on whether 
ataxia was permanent. Webster, et al. (49) demonstrated recovery 
of post-rotatory nystagmus and of normal electronystagmographic 
measurements in at least two cats kept six months after courses of 
topical middle ear applications of gentamicin. Recovery of caloric 
response six months after a course of systemic gentamicin was also 
demonstrated on 40% of the cats studied by McGee, et al. (50). 
However, Waitz, Mors and Weinstein (51) stated that the vestibular 
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damage "appeared to be irreversible." The three cats they tested 
were given a course of 40 mg/kg/day which was twice the dose used 
in the above two studies where vestibular recovery was demonstrated. 
Also, these animals were only allowed forty-five days to recover be¬ 
fore having the gentamicin regimen resumed to the point of renal 
tubular necrosis and death. All three cats were ataxic for the forty- 
five days but this fact does not support their conclusion of "irrever¬ 
sible" vestibular damage especially when compared to the 6 months needed 
for recovery in the Webster (49) and McGee (50) studies. In light of 
these experiments, it would be interesting to know the recovery time 
of the 14 patients described by Arcieri and Jackson (54). 
In an attaript to determine factors of general importance in the develop¬ 
ment of human ototoxicity, Jackson and Arcieri (54) performed a stepwise 
discriminant function analysis which revealed one outstanding difference 
between patients suffering gentamicin ototoxicity and the control group. 
Persons with eighth nerve damage had a significantly higher incidence 
of impaired renal function (p<.0001). In addition, of the ototoxic 
patients with renal impairment, 35% had had prior courses of ototoxic 
antibiotics whereas none of the persons with renal impairment but with¬ 
out ototoxic manifestations had received similar prior therapy. Total 
dose was not found to be significantly different between groups nor 
was the number of days of treatment. Age, which earlier had been 
thought to have a direct correlation with increasing toxicity (53) 
was not found to be an important factor by these investigators, 
who eliminated many untested or poorly tested children from the 
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control sample, and then compared this group with the 70 suspected 
cases of ototoxicity and found no significant age difference between 
the groups. Jackson and Arcieri summarized their data by stating 
1) that the true incidence of gentamicin ototoxicity over a four-year 
period in the U.S. (1966-1969) is 2%, 2) that the overwhelmingly 
important factor in the occurrence of eighth nerve dysfunction in any 
one patient is that patient's renal function, and 3) that only in 
cases of renal insufficiency were previous courses of ototoxic anti¬ 
biotics a risk factor. Because increasing daily dose per kilogram 
and not total dose were related to ototoxic effects, they also felt 
that toxicity must be related to serum concentrations. They noted that 
over 50% of the ototoxic group but only 22% of the control group had 
concentrations over 8 ug/ml, and recommended monitoring serum levels of 
gentamicin (54). 
The toxicities of systemic gentamicin have been better understood by 
extensive and often elegant animal and human studies. They allow the 
clinician using this drug not only to know the incidence of life-threaten¬ 
ing or especially prominent adverse effects, not only to see examples 
of the disruption on an electron-microscopic level, but also to under¬ 
stand which factors in his own patient enhance the risk of toxicity. 
The physician then has monitoring techniques to create a personalized 
regimen for this patient. 
When gentamicin is administered directly into the CSF, are the known 
toxicities more severe? Are there new toxic effects to CNS tissues? 
During a discussion in the 1971 gentamicin symposium, Hawkins stated that 
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"the intrathecal route offers a direct line of 
communication by way of the perilymphatic duct 
and cochlear aquaducts to the basal turn of the 
cochlea. We have found in cats (and I would not 
want to overstress the applicability of animal 
experiments to these matters) that the dose of 
streptomycin and neomycin required to produce 
severe ototoxicity when given by the intracister- 
nal route is of the order of 1% of that required 
by the intramuscular route." p.S620 (55). 
Considering the possibility that gentamicin is analogous to strepto¬ 
mycin and neomycin, and that human ears are analogous to those of cats, 
Hawkins's comments give rise to worry over the toxic effects of any 
intra-CSF gentamicin regimen. The present neonatal and infant 
studies do not contain followup evaluations of the child’s vestibular 
and auditory function. Followup in adult meningitis patients has 
also been poor, although several patients with CSF concentrations equal 
or above those of the serum have been said to recover without neurologi¬ 
cal sequelae. To understand whether intrathecal or intraventricular 
gentamicin enhances ototoxicity, more clinical studies with long-term 
followup are required. 
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The purpose of this study was to provide additional clinical infor¬ 
mation about the efficacy and toxicity of intrathecal (IT) and in¬ 
traventricular (iVt) gentamicin when used in patients with gram¬ 
negative bacillary meningitis. An investigational preparation of 
gentamicin in saline without the usual chelating agent, anti-oxident, 
and paraben preservatives was given to patients intrathecally or 
intraventricularly. The efficacy and toxicity of this preparation 
was compared to those of commercial gentamicin administered in the 
same way. 
Three areas of investigation were concentrated on in this study. 
A. Patients receiving the investigational preparation had multiple 
CSF and serum gentamicin assays performed during antibiotic therapy. 
These determinations provided opportunity to correlate 1) dosage with 
CSF concentration, 2) CSF concentrations over time, 3) and serum 
levels with CSF levels. 
B. Efficacy in all cases of meningitis treated with gentamicin was 
analyzed not only in terms of the investigational or commercial pre¬ 
paration used but also according to the age of the patient, the in¬ 
fecting organism, and the concurrent use of additional antibiotics. 
The regimen including intrathecal or intraventricular gentamicin in 
treating gram-negative bacillary meningitis at Yale New Haven Hos¬ 
pital was then compared to regimens using only systemic antibiotics. 
C. Toxicity was evaluated through review of the patient's hospital 
course and followup examinations. Particular attention was paid 
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to any evidence for acute, renal, vestibular, or auditory toxicity 
for either the investigational or commercial preparation. 
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Materials and Methods 
Patients: Nineteen patients, 11 adults and 8 infants, with sus¬ 
pected gram-negative meningitis were treated with intrathecal and 
systemic gentamicin alone and with other antibiotics. 
After protocol approval by the Yale University Human Investigation 
Committee, an investigational preparation was made available for use. 
The protocol delineating both intrathecal or intraventricular and 
systemic gentamicin treatment was fully explained to the responsible 
person in each case and a signed consent form was obtained before 
initiation of therapy. All patients receiving the investigational 
preparation intrathecally or intraventricularly also received concomit¬ 
ant commercial gentamicin intramuscularly in a dose of 3-5 mg/kg/day. 
Eleven patients, 6 adults and 4 infants with bacteriologically proven 
meningitis due to a gram-negative organism, and one adult with sus¬ 
pected meningitis, were given the investigational preparation. 
For comparison, the charts of all previous Yale-New Haven Hospital 
patients who received the commercial gentamicin preparation intrathec¬ 
ally or intraventricularly were reviewed. Eight patients, A adults 
and 4 infants including one infant without culture positive CSF 
infection, received the commercial preparation. 
In the investigational group, CSF gentamicin concentrations were 
then correlated with dosage, duration of therapy, and serum levels. 
All cases of bacteriologically proven meningitis in both the investi¬ 
gational and commercial groups (18 cases in 17 patients) were analyzed 
according to cure rate in comparison with the type of infecting 
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organism, age of patient, and use of additional antibiotics. 
Acute toxic reactions in addition to renal and ototoxicities 
were evaluated in all patients of both the investigational and 
commercial groups (19 patients). Comparisons of efficacy and 
toxicity were then made according to the preparation used. 
Investigational Preparation: Gentamicin sulfate in saline 
(2 mg/cc) was provided by Dr. George Arcieri of Schering Corp. In 
contrast to the current commercial preparation, this solution does 
not contain 1) the chelating agent, disodium ethylenediamine-tetra- 
acetate dihydrate, 2) the antioxident, sodium bisulfate, nor 3) the 
preservatives, methyl and propylparabens. Recommended intra-CSF 
doses were 1-2 mg/24 hrs in infants and 2-r4 mg/24 hrs in adults. 
The drug was administered by barbatage and vital signs monitored 
during the slow infusion. 
Bioassay: The method of Winters, Litwack, and Hewitt (56) as 
modified in our laboratory was employed to determine gentamicin 
levels. This method utilizes an agar-diffusion assay which requires 
only small quantities of body fluids (0.02 ml Serum or CSF) and 
affords results within 5 hours. A standard solution of gentamicin 
sulfate in distilled water is made monthly and frozen. Concentra¬ 
tions of 20, 10, 5, 2.5, 1.25 and 0.625 ug/ral are made which are 
suitable for linear regression calculations. The test organism is 
Bacillus qlobiqii, an unclassified spore-former with a MIC of gentami¬ 
cin of 0.5 ug/ml. It is maintained on nutrient agar slant (DIFCO) 
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and transferred weekly. The organism is prepared by trans¬ 
ferring a few colonies to 30 ml of brain-heart-infusion broth 
and grown for 6 hours at 37°C resulting in approximately 10-10 
organisms per ml. To prepare the plates, 3 ml of this 6-hour 
culture is added to 36 ml of modified tryticase soy agar (BBL). 
(Modification--26.66 gm. of agar are added to 1000 ml of distilled 
water giving a final pH of 7.3). Thirty-six ml of this mixture is 
poured into petri dishes and allowed to solidify. It is further 
cooled by refrigeration for 15 minutes. If the patient has 
received any of the penicillins, 1.0 ml of penicillinase (DIFCQ) 
is added to the mixture before cooling. If the patient is receiving 
oxacillin or a cephalosporin, another organism, Enterobacter aeroqenes 
is used in place of Bacillus qlobiqli for the bioassay. This organism 
is resistent to oxacillin and produces a cephalosporinase. However, 
this cephalosporinase has recently been found not to inactive cefazo- 
lin. Therefore, when the patient is receiving cefazolin, 1 ml of 
reconstituted beta lactamese, broad spectrum mixture (Whatman) is 
added to each plate in order to inactivate cefazolin. Wells pro¬ 
duced with a blunt 4 mm diameter bore are filled in duplicate with 
the standards and the patients serum or CSF, using a nonheparinized 
capillary tube. The plates are then incubated overnight at 37°C. 
The diameter of the zone of inhibition is read for both standards 
and unknown with a millimeter ruler. The concentration of the 
antibiotic standards (ug/ml) with its mean inhibition zone 
diameter (mm.) as well as the unknown’s mean zone sizes are 
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entered on a Monroe calculator which then computes the concentra¬ 
tions of the unknown through linear regression analysis. 
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Results 
A. CSF gentamicin concentrations? Cerebrospinal fluid obtained 24 
hours (± 2 hrs.) after intrathecal or intraventricular instillation 
of 3 or 4 mg. of gentamicin in adults and 1 or 2 mg. of gentamicin 
in infants, resulted in 33 determinations ranging from 1.35 ug/ml to 
24.3 jpg/ml with a mean of 6.69 pg/ml. These determinations,referred 
to as 24 hr. CSF concentrations, were made from day 2 to day 16 of 
IT or IVt therapy. In order to study the 24 hr. CSF levels over the 
course of therapy, gentamicin concentrations were plotted for individual 
patients over time (fig. l). Although the same regimen of gentamicin 
therapy was continued in these patients, 24 hr. CSF levels of gentamicin 
were noted to decrease over time. All 24 hr. CSF concentration values 
were graphed according to day of intrathecal or intraventricular therapy, 
fig. 2. Concentrations on Days 1-6 were found to be significantly 
higher than those on Days 7-13 (p<.00l) (mean days 1-6 = 9.168 ug/ml 
SE = 1.36, mean days7-ISF3.149 pg/ml SE- .65). In no patient was there 
an indication of gentamicin accumulation in the CSF over time. In order 
to determine whether there were changes in opening pressure of the lumbar 
punctures over the course of therapy which were related to the decreasing 
CSF gentamicin levels, opening pressures were plotted over time in six 
patients (fig. 3). No trend in these pressures over the course of 
therapy was observed. 
In several instances, CSF and serum samples were drawn from the 
same patient at the same time. The cerebrospinal fluid and serum 
were obtained 24 hours (± 2 hours) after the last intrathecal or 
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intraventricular dose and 4-6 hours after the previous systemic 
dose. Linear regression analysis of the simultaneous concentrations 
revealed no significant correlation between the CSF and serum values 
(r = .44). In addition, the interval between the last systemic dose 
of gentamicin and withdrawal of the CSF sample was plotted against 
the gentamicin concentration in that CSF sample in order to investi¬ 
gate any possible effect of systemic gentamicin therapy on 24 hr. 
CSF levels (fig. 4). As shown in figure 4 the number of hours after 
systemic administration did not affect the 24 hr. CSF levels. Finally, 
in order to look at the effect of intrathecal or intraventricular gen¬ 
tamicin administration on serum levels in our patients as compared to 
serum profiles of gentamicin concentrations reported earlier in the 
literature, serum concentrations at varying intervals after systemic 
dosage are illustrated in fig. 5. The serum profiles in our patients 
do not differ from the range reported in patients who did not receive 
CSF instillation of the antibiotic (20,5,6). 
B. Efficacy: Eighteen cases of meningitis in seventeen patients, ten 
adults and seven infants, were bacteriologicaliy proven to be caused 
by gram-negative bacillary organisms. One newborn suffered reinfection 
(Proteus Mirabilis then E. coli) accounting for the eighteen meningeal 
infections in seventeen patients treated with intrathecal or intraven¬ 
tricular gentamicin. Thirteen bacteriologic cures were obtained (72%). 
The patient's age, infecting organism, and number of days of IT or IVt 
therapy required to sterilize the CSF are shown in Table 1. 
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Investigational preparation? 
Patient_Age_Organism # Days to 
A.P. 59 Klebsiella 13 
W.P. 56 Klebsiella 1 
H.D. 35 Proteus Mirabilis 
Bacteroides 
5 
M.M. 45 Ps. Aerugenosa 2 
D.C. 58 E. coli 7 
C.L.* 31 Pseudomonas & 
Proteus Mirabilis 
B.L. Newborn Proteus Mirabilis 11 
D.L.* 1 mo. _E. coli 12 
B.C.* Newborn Ps. Aerugenosa - 
L.C** Npwborn a) Proteus Mirabilis 3 
b) E. coli 7 
Commercial Preparations 
V. D 60 E. coli 1 
A.G 57 E. coli 10 
N.P* 42 Klebsiella - 
G.R 23 Ps. Aerugenosa 4 
S. H 9 mo. Flavobacter 5 
A.M. 2 mo. Klebsiella 4 
* 
G.C. Newborn E. coli - 
^Treatment failures 
sterile CSF 
(last CSF before 
death sterile but 
signs of active 
infection present 
at autopsy) 
(but then relapse) 
(Antib. D/Cal) 
^•Reinfection - 2 courses of therapy 
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There was no difference in the bacteriologic cure rate between 
patients who received the investigational preparation and those 
treated with commercial gentamicin (Table 2). 
Table 2 
Gentamicin 
Investigational 
Cures Failures 
Adult 
cases 5 1 
Infant 
cases _3 (in 2 2 
infants) 
Totals 8 3 
$ cured 73$ 
Commercial 
Cures Failures 
3 1 
2 1 
5 2 
71$ 
Eleven of the seventeen patients with bacteriologically proven 
meningitis survived the hospitalization (6 adults and 5 infants). 
This group differed from the one designated as"cures" (8 adults 
and 4 infants) in the following ways: one adult (A.P.) whose 
Klebsiella meningitis was cured, died one month later after a 
second surgical procedure for removal of a frontal meningioma; 
a second adult (D.C.) died suddenly three months after cure of his 
E. coli meningitis while awaiting nursing home placement; one infant 
who suffered from hydrocephalus, had sterile CSF 12 days after initia¬ 
tion of IVt gentamicin therapy for E. coli meningitis, but then 
suffered a relapse which was successfully treated with chlorampheni¬ 
col. Therefore, this infant was considered a gentamicin treatment 
"failure" but survived the hospitalization. 
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The infecting organisms, number of cures and treatment fail¬ 
ures are shown in Table 3. Treatment failures occurred with 
Klebsiella and E. coli infections as well as a mixed Pseudomonas 
and Proteus M. infection. The infant with Ps_. aeruginosa menin¬ 
gitis complicating a meningomyelocele was considered a treatment 
failure for this study. However, antibiotic therapy was discon¬ 
tinued after four days of treatment. The baby did live an addi¬ 
tional 22 days with no systemic signs of meningitis (fever or 
seizures) but no further CSF samples were obtained. 
Table 3 
Orqanism Cure Failure Total % Cured 
E. coli 4 2 6 66 
Klebsiella 3 1 4 75 
Ps. Aeruginosa 2 1 3 60 
Proteus Mira- 
bilis 2 0 2 100 
Flavobacter 1 0 1 100 
Proteus Mira- 
bilis & 
Bacteroides 1 0 1 100 
Pseudomonas 
& Proteus 
Mirabilis 0 1 1 0 
Total 13 5 18 72% 
In eleven of the thirteen cured cases of meningitis, antibiotics 
in addition to gentamicin were given concurrently. In order to 
further delineate the effect of these additional antimicrobial 
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agents on the successful treatment of these infections, the 
eleven cases were divided into those receiving "effective" 
and "noneffective antibiotics. This separation was made accord¬ 
ing to in vitro sensitivity studies and the ability of the addi¬ 
tional antibiotic to penetrate the CSF. Using this criteria, 
seven patients were in the "effective" antibiotic group (64%). 
Six patients comprised the "noneffective" graup including one 
patient who received chloramphenicol but whose Pseudomonas or¬ 
ganism was not sensitive to that drug, 3 patients receiving 
antimicrobials which do not penetrate the CSF, and two patients 
who received only gentamicin. Therefore, in six of thirteen in¬ 
stances (55%) treatment success could be specifically attributed 
to intrathecal gentamicin. 
In addition to meningitis, patients had a wide range of under¬ 
lying diseases or congenital defects. Eight of ten adults had 
a prior neurosurgical procedure. The ninth adult patient had an 
automobile accident resulting in a basilar skull fracture, and 
the tenth suffered from diabetes mellitus, alcoholism, and septi¬ 
cemia in addition to gram-negative bacillary meningitis. Four of 
the seven infants had meningomyeloceles and/or hydrocdphalus. 
Two of the remaining three infants were premature and the other 
was considered normal when delivered at term. 
In order to compare the efficacy of antibiotic regimens which 
included intrathecal or intraventricular gentamicin with solely 
systemic antibiotic therapies, all cases of gram-negative 
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bacillary meningitis at the Yale affiliated hospitals were re¬ 
viewed between the period of September 1968 and June 1974. To 
partially minimize the variation in treatment methods, analysis 
was restricted to only those cases in which either the systemic 
regimen or the intrathecal gentamicin regimen was begun promptly 
(within 48 hours) after isolation of the CSF organism. Nine 
failures occurred in 20 cases treated with only systemic anti¬ 
biotics (45/d). Two treatment failures occurred in thirteen cases 
treated with IT or IVt gentamicin (15%). This difference was 
not statistically significant (p<0.20), however the trend in¬ 
dicated that better therapeutic results are obtained when intra¬ 
thecal or intraventricular gentamicin is part of the antibiotic 
regimen. 
C. Toxicity: 
Renal toxicity was evaluated in 19 patients treated with genta¬ 
micin both IT and IVt in terms of abnormal BUN and creatinine values 
during or immediately after termination of gentamicin therapy. 
On this basis, none of the nineteen patients experienced renal 
toxicity. No acute toxicity during or immediately after the in¬ 
stillation of gentamicin was observed in 18 of 19 patients in¬ 
cluding one adult who inadvertently received 20 mg II during 
one infection. One woman did develop bilateral lower extremity 
pain and muscle spasm during intrathecal gentamicin administration 
and later during intrathecal instillation of Polymyxin B. After 
discharge the patient complained of lower extremity weakness, 
and was noted to have bilateral weakness of flexor muscles of the 
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hip as well as sensory loss from S2 to S5. Evaluation of this 
problem was complicated by her underlying disease, metastatic 
breast cancer, which caused her death four and one-half months 
after discharge. 
Ototoxicity, both auditory and vestibular, was extremely diffi¬ 
cult to evaluate during hospitalization because of the desperately 
ill condition of these patients and the fact that 8 of 19 were 
infants. However, no clinical evidence of clear gentamicin toxicity 
was noted in eight patients, 5 adults and 3 infants, who were 
followed for four months to 3 years after intrathecal therapy. 
Two adults and 2 infants of this group received the investigational 
preparation. Three adults and one infant received the commercial 
preparation. No difference in toxicity was noted between the 
investigational and commercial preparations. Three patients were 
lost to followup. One of the children was noted to have a broad 
gait 2 years after therapy. This could be considered as evidence 
for gentamicin induced vestibular damage. However, the child had 
had surgical exploration of the posterior fossa during which a por¬ 
tion of cerebellum containing the dentate nucleus was removed. 
Another infant remains severely retarded, cortically blind and 
without control of her lower extremities, bladder or bowel function 
3 years after a protracted hospital course for meningomyelocele 
repair and multiple ventricular shunts. She could not be evaluated 
for long term toxic effects of gentamicin therapy. 
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Discussion 
The ability to measure by bioassay, concentrations of genta¬ 
micin over the course of therapy has demonstrated a surprising 
range of 24-hour CSF concentrations in patients receiving equiva¬ 
lent doses. Previous studies, usually on a smaller number of 
patients, corroborate the wide range of CSF concentrations which 
may be expected even though equivalent doses of 4 mg in adults 
and 1 mg in infants are given intrathecally or intraventricularly. 
(25,26,27,30,36,37). 
The issue of transfer of gentamicin from serum to CSF or vice 
versa, was speculated upon extensively in the early literature 
on gentamicin placement in the CSF (14,20,23). When simultaneous 
serum and CSF values were compared in our patients, no significant 
correlation between the two levels was observed. In addition, 
systemic administration of gentamicin was not noted to affect CSF 
concentrations, and intrathecal or intraventricular administration 
of the antibiotic did not alter our patient's serum levels from 
the profiles described by Winters, et al. (56) and Rodriquez, 
et al. (20). 
Rahal, et al. (36) recently observed a rapid decline in CSF 
concentrations during the initial 24 hr* period in 21 patients 
receiving IT gentamicin. Two-thirds of their samples drawn at 
20 hours post instillation contained less than 3jjg/ml. This 
finding caused these authors to conclude that, "Intrathecal 
injections of 4 mg of gentamicin must be repeated at least every 
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18 hours to maintain therapeutic concentrations in lumbar cere¬ 
brospinal fluid." p. 1394 (36). Their findings and conclusion 
are not supported by our data. Twenty-three of 33 CSF gentamicin 
levels (7Q%), determined at 24 hours (+ 2 hours) after the prev¬ 
ious intrathecal or intraventricular dose of 4 mg in adults and 
1 mg in infants, were above 3 pg/ml. The mean of 6.69 ug/ml and 
median of 5.0 ug/ml were also well above the values reported by 
Rahal, et al. (36). On the oasis of our data, doses of 4 mg IT 
in adults and 1 mg IT or IVt in infants every 24 hours gives 
adequate CSF levels (^3 pg/ml) in 70% of samples. We, therefore, 
do not feel that instillation every 18 hours should be adopted 
as standard therapy. However, we strongly recommend that direct 
monitoring of CSF concentrations be performed in all patients. 
The fact that concentrations in the CSF decreased significantly 
over the course of therapy in our patients is an interesting al¬ 
though not readily explainable finding. The previously cited 
studies on the flow of CSF and distribution of labeled molecules 
within the fluid indicate that a lumbar injected material may have 
minimal diffusion if injected in a small volume (38,39,40). If 
a similar method was used each day for a particular patient, then 
an intra-cerebral change must be postulated for altered distri¬ 
bution and/or excretion of the gentamicin as the meningitis 
improves. When gentamicin was deposited intra-ventricularly in 
two infants, 24 hour concentrations over several days did not show 
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declines similar to those of adults receiving IT injections. 
Perhaps then, tissue inflammation and low grade obstruction 
prevents normal flow and dispersal of the drug throughout the 
CSF at the onset of treatment. But excretion of CSF at the 
arachnoid villi could also be decreased by the same mechanism. 
Davson (57) has described the arachnoid villi as made up of 
aggregates of tubes which open or collapse according to pressure, 
operate as a valvular mechanism. In monkeys the critical pressure 
difference is 25-50 mm of saline. These villi allow passage of 
virtually any size particle including large proteins. Rail and 
Zubrod (58) in their review of the mechanism of passage of drugs 
in and out of the CSF, noted that several investigators demon¬ 
strated active absorption of organic acids from the CSF. This 
absorption was localized to the choroid plexus in the fourth 
ventricle. They suggested that a similar mechanism of removal 
of organic bases from Ithe CSF might also exist, and noted the 
similarity between the choroid plexus and the renal tubule. 
Andriole (59) has noted that the aminoglycosides behave as weak 
bases. Whether gentamicin might actively be absorbed from the 
CSF via the choroid plexus is not known, but this might be a 
factor in the variable concentrations obtained with a standard dose. 
However, without excretion studies in animals with meningitis, using 
labeled gentamicin, no definitive explanation for this statistically 
significant decline can be given at this time• 

48 
The efficacy of a regimen containing IT or IVt gentamicin 
against a variety of gram-negative organisms is demonstrated by 
bacteriologic cure in 72% of our cases. As observed above, this 
rate is higher than that of previous regimens employed at this 
hospital and even in this small group of patients comes close to 
attaining statistical significance. By separating the "cured" 
cases into those receiving effective and noneffective additional 
antibiotics, 55% of the bacteriologic cures could be directly 
attributed to gentamicin administration. The infant mortality 
rate of this study was 2 of 7 patients with bacteriologically 
proven infection. One child died within 24 hours of overwhelming 
E. coii sepsis and meningitis, the other death occurred 22 days 
after discontinuance of antibiotic therapy and at that time the 
child showed no clinical evidence of CSF infection. Excluding the 
latter ease, the gentamicin treated infants had an 80% survival 
rate which is definitely higher than those of earlier studies. 
Groover et al. (60) reported an 11 year review in which 41% of 
purulent newborn meningitis was caused by gram-negative organisms 
and 81% of these infants died as a result of their infection. An 
earlier report by Ziai and Haggerty (61) included 83 cases of 
meningitis with 62 deaths and 30 of 77 cases with culture positive 
CSF were due to gram-negative bacilli. Although an overall im¬ 
pression of improvement in survival rates with intra-CSF gentamicin 
is probably justified, it is very difficult l) to compare studies 
done in different institutions at different times often with 
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differing doses of antibiotic, 2) to compare studies done in the 
same institution when the patients differ not only in their own 
risk and host defense factors but in the various neurosurgical 
procedures they have experienced,and finally 3) to compare the 
role of one drug when it is used in combination with several other 
antibiotics against a variety of organisms. Dissection of this 
tangle of variables cannot be accomplished until many more patients, 
treated with fewer regimens, are carefully studied. Certainly the 
data presented here provides additional evidence favoring prompt 
treatment of gram-negative bacillary meningitis with IT or IVt 
gentamicin. 
The only toxicity observed in the 19 patients who received 
CSF instillations of gentamicin in this study was that of acute pain 
in the lower extremities in one adult patient when she received 
either intrathecal gentamicin or intrathecal Polymyxin B. As 
described earlier this woman continued to have pain and dysfunction 
of her lower extremities as an outpatient. This was attributed 
to nerve root inflammation and destruction caused by IT antibiotics. 
When she died 1 month later because of widely disseminated breast 
cancer, the diagnosis of toxicity rather than metastatic damage 
was less certain. This case is one example of the difficulty in 
attributing any sensory or motor loss in a neurosurgical or neo¬ 
natal patient with meningitis to the toxicity of the antibiotic. 
To obtain an accurate audiogram in a desperately ill adult is 
impossible, in a neonate unproductive, and in an adult with sus¬ 
pected but untested prior diminished acuity, meaningless. It is 
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equally difficult to accurately test for vestibular ataxia or 
nystagmus under these conditions. Surveillance for any sign of 
renal failure followed by appropriate dosage and adjustment has 
been shown to be the most important factor in prevening eighth 
nerve toxicity when gentamicin is given systemically (54). The 
absence of auditory and vestibular toxicity then is not surprising 
in this group of patients who were without renal dysfunction. 
Followup studies from 4 months to 3 years in eight patients (5 adults 
and 3 infants) provide some of the longest post-gentamicin evalua¬ 
tion periods recorded in the literature on IT or IVt gentamicin. 
The fact that these 8 patients suffered no toxicity indicates 
that CSF concentrations often above 10 ug/ml at 24 hours and pre¬ 
sumably higher soon after the instillation, can be well tolerated 
in both adults and infants. The ototoxicity feared by Dr. Hawkins 
with CSF concentrations merely 1% of serum levels producing rapid 
vestibular dysfunction in animals (55) was not seen in this study. 
In fact we have no Evidence to indicate that gentamicin in the CSF 
at or above usual serum levels is any more toxic than the systemic- 
ally delivered drug. 
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Intrathecal or intraventricular daily doses of 4 mg of genta¬ 
micin in adults and 1 mg. in infants was found to produce a 
wide range of antibiotic concentrations (24.3 to 1.34 yg/ml) 
in CSF fluid withdrawn 24 hours later. 
Instillation of gentamicin into the CSF did not appear to affect 
serum concentrations. Serum profiles in our patients corres¬ 
ponded to those described previously in the literature. In 
addition, intramuscular and intravenous administration of genta¬ 
micin did not affect 24 hour CSF levels in a predictable fashion. 
Daily doses of 4 mg IT in adults and 1 mg IT or IVt in infants 
produced therapeutic levels ( 3 ug/ml) in 70$ of CSF samples 
drawn 24 hours later. Data obtained in this study do not support 
the previous recommendation by others that instillation is re¬ 
quired every 18 hours. If possible, each patient's infection 
should be managed with serial monitoring of serum and CSF con¬ 
centrations. 
CSF concentrations of gentamicin decreased significantly over 
time even though the patient received the same daily intrathecal 
dose. 
A regimen including instillation of gentamicin into the CSF cured 
72$ (13 of 18) of gram-negative bacillary infections treated in 
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this study. This cure rate was higher than that of previous 
systemic antibiotic regimens (45%) used in this hospital. No 
difference in efficacy was demonstrated between the investiga¬ 
tional and commercial gentamicin preparations. 
Within the limits of this study, no evidence of vestibular, audi¬ 
tory, or renal toxicity was found during or after therapy with 
either the investigational or commercial gentamicin preparation. 
One patient reported pain during intrathecal administration of 
the investigational preparation and also when receiving intrathecal 
Polymyxin B. 
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